Distinct expression of Kaposi’s sarcoma‐associated herpesvirus‐encoded proteins in Kaposi’s sarcoma and multicentric Castleman’s disease

The expression of Kaposi’s sarcoma‐associated herpesvirus (KSHV/HHV‐8)‐encoded proteins is herein demonstrated in Kaposi’s sarcoma (KS) and multicentric Castleman’s disease (MCD) in a single lymph node derived from a patient with acquired immunodeficiency syndrome. Immunohistochemistry revealed that both lytic and latent KSHV proteins were expressed in cells of the MCD lesion. KSHV‐encoded viral interleukin‐6 was also detected in follicular dendritic cells of the germinal center. Cytoplasmic localization of open reading frame 59 protein and latency‐associated nuclear antigen suggested KSHV activation in the MCD lesion. Moreover, a high copy number of KSHV was detected in the blood. Clinically, pegylated‐liposomal doxorubicin induced regression of not only KS, but also lymphadenopathy of the MCD lesion with a decrease in KSHV load and human interleukin‐6 in the blood. To the best of the authors’ knowledge this is the first case demonstrating differential expression of virus proteins in two KSHV‐associated diseases, KS and MCD, in the same section. The case confirms lytic KSHV infection in MCD, and suggests that clinical symptoms of MCD might be closely linked with KSHV activation.

[1]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[2]  R. Ricciardi,et al.  Processivity factor of KSHV contains a nuclear localization signal and binding domains for transporting viral DNA polymerase into the nucleus. , 2005, Virology.

[3]  C. Casper,et al.  The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care , 2005, British journal of haematology.

[4]  M. Du,et al.  Pathology of bone marrow in human herpes virus‐8 (HHV8)‐associated multicentric Castleman disease , 2004, British journal of haematology.

[5]  A. Wald,et al.  Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. , 2004, Blood.

[6]  M. Cornelissen,et al.  Multicentric Castleman's disease and Kaposi's sarcoma in a cyclosporin treated, HIV-1 negative patient: case report , 2003, BMC blood disorders.

[7]  J. Bourhis,et al.  A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody , 2003, Annals of Hematology.

[8]  P. Moore,et al.  Viral IL-6-Induced Cell Proliferation and Immune Evasion of Interferon Activity , 2002, Science.

[9]  G. Delsol,et al.  HHV‐8 infection status of AIDS‐unrelated and AIDS‐associated multicentric Castleman's disease , 2001, Pathology international.

[10]  J. Manning,et al.  Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy , 2001, Cancer.

[11]  S. Pittaluga,et al.  Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. , 2001, Blood.

[12]  P. Brousset,et al.  Detection and characterization of human herpesvirus-8-infected cells in bone marrow biopsies of human immunodeficiency virus-positive patients. , 2001, Human pathology.

[13]  B. Chandran,et al.  Characterization of Human Herpesvirus 8 ORF59 Protein (PF-8) and Mapping of the Processivity and Viral DNA Polymerase-Interacting Domains , 2000, Journal of Virology.

[14]  É. Oksenhendler,et al.  High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. , 2000, Blood.

[15]  N. Saini,et al.  Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Inagi,et al.  Human herpesvirus 8‐encoded interleukin‐6 homologue (viral IL‐6) induces endogenous human IL‐6 secretion , 2000, Journal of medical virology.

[17]  D. Podzamczer,et al.  Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin , 2000, AIDS.

[18]  S. Mori,et al.  Identification of Antigenic Proteins Encoded by Human Herpesvirus 8 and Seroprevalence in the General Population and among Patients with and without Kaposi's Sarcoma , 2000, Journal of Virology.

[19]  S. Mori,et al.  Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. , 2000, Virology.

[20]  W. Rozenbaum,et al.  Quantitative Analysis of Human Herpesvirus 8 Viral Load Using a Real-Time PCR Assay , 2000, Journal of Clinical Microbiology.

[21]  M. Corbellino,et al.  Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. , 2000, The American journal of pathology.

[22]  S. Sakurada,et al.  Expression and antigenicity of human herpesvirus 8 encoded ORF59 protein in AIDS‐associated Kaposi's sarcoma , 1999, Journal of medical virology.

[23]  H. Satoh,et al.  Establishing and characterizing a CD30‐positive cell line harboring HHV‐8 from a primary effusion lymphoma , 1999, Journal of medical virology.

[24]  S. Mori,et al.  High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. , 1999, The American journal of pathology.

[25]  E. van Marck,et al.  Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Herrada,et al.  The Clinical Behavior of Localized and Multicentric Castleman Disease , 1998, Annals of Internal Medicine.

[28]  B. Chandran,et al.  Identification and characterization of human herpesvirus-8 lytic cycle-associated ORF 59 protein and the encoding cDNA by monoclonal antibody. , 1998, Virology.

[29]  G. Gaidano,et al.  Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. , 1997, Blood.

[30]  M. Corbellino,et al.  Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. , 1997, The American journal of pathology.

[31]  C. Boshoff,et al.  Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV , 1996, Science.

[32]  S. Imai Mouse mammary tumor virus and mammary tumorigenesis in wild mice. , 1996, Pathology international.

[33]  M. Yamakawa,et al.  Morphology, function and pathology of follicular dendritic cells , 1996, Pathology international.

[34]  R. Sun,et al.  Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. , 1996, The New England journal of medicine.

[35]  I. Sesterhenn,et al.  Lymphoid changes of the nasopharyngeal and palatine tonsils that are indicative of human immunodeficiency virus infection. A clinicopathologic study of 12 cases. , 1996, The American journal of surgical pathology.

[36]  M. McGrath,et al.  Lytic growth of Kaposi's sarcoma–associated herpesvirus (human herpesvirus 8) in culture , 1996, Nature Medicine.

[37]  F. Sigaux,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.

[38]  B. Klein,et al.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. , 1994, The New England journal of medicine.

[39]  A. Dalgleish,et al.  Kaposi's sarcoma. , 1991, British Journal of Cancer.

[40]  A. Stansfeld,et al.  An immunohistological and genotypic study of the plasma cell form of Castleman's disease , 1989, Histopathology.

[41]  B. Peterson,et al.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  B. Nathwani,et al.  Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. , 1985, Human pathology.

[43]  P. Banks,et al.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: Pathological findings in 15 patients , 1983, The American journal of surgical pathology.

[44]  E. Robertson,et al.  OF KAPOSI ’ S SARCOMA-ASSOCIATED HERPESVIRUS , 2002 .

[45]  Y. Shima,et al.  Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. , 2000, Blood.

[46]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. , 1989, Blood.